Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists: A National, Multicenter, Retrospective Cohort

Authors:
  • JTJean-Luc Tremblay
    Jean-Luc Tremblay
  • CTCarter Thorne
    Carter Thorne
  • VBVivian P. Bykerk
    Vivian P. Bykerk
  • JLJuris Lazovskis
    Juris Lazovskis
  • KBKenneth L.N. Blocka
    Kenneth L.N. Blocka
  • MBMary J. Bell
    Mary J. Bell
  • DLDiane Lacaille
    Diane Lacaille
  • CHCarol A. Hitchon
    Carol A. Hitchon
  • AFAvril A. Fitzgerald
    Avril A. Fitzgerald
  • WFWesley K. Fidler
    Wesley K. Fidler

Abstract
Objective.: To describe early rheumatologic management for newly diagnosed rheumatoid arthritis (RA) in Canada.Methods.: A retrospective cohort of 339 randomly selected patients with RA diagnosed from 2001–2003 from 18 rheumatology practices was audited between 2005–2007.Results.: The most frequent initial disease-modifying antirheumatic drugs (DMARD) included hydroxychloroquine (55.5%) and methotrexate (40.1%). Initial therapy with multiple DMARD (15.6%) or single DMARD and corticosteroid combinations (30.7%) was infrequent. Formal assessment measures were noted infrequently, including the Health Assessment Questionnaire (34.6%) and Disease Activity Score for 28 joints (8.9%).Conclusion.: Initial pharmacotherapy is consistent with guidelines from the period. The infrequent reporting of multiple DMARD combinations and formal assessment measures has implications for current clinical management and warrants contemporary reassessment.

This publication has 10 references indexed in Scilit: